JAYPIRCA Drug Patent Profile

When do Jaypirca patents expire, and when can generic versions of Jaypirca launch?

Jaypirca is a drug marketed by Loxo Oncol and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and six patent family members in forty countries.

The generic ingredient in JAYPIRCA is pirtobrutinib. One supplier is listed for this compound. Additional details are available on the pirtobrutinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Jaypirca

Jaypirca will be eligible for patent challenges on January 27, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 14, 2041. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for JAYPIRCA

International Patents:	106
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	23
Clinical Trials:	1
Patent Applications:	125
Drug Prices:	Drug price information for JAYPIRCA
What excipients (inactive ingredients) are in JAYPIRCA?	JAYPIRCA excipients list
DailyMed Link:	JAYPIRCA at DailyMed

See drug prices for JAYPIRCA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for JAYPIRCA

NDA:

216059

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for JAYPIRCA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medical College of Wisconsin	Phase 1

See all JAYPIRCA clinical trials

Pharmacology for JAYPIRCA

Drug Class	Kinase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Bruton's Tyrosine Kinase Inhibitors Cytochrome P450 2C19 Inhibitors Cytochrome P450 2C8 Inhibitors Cytochrome P450 3A Inhibitors P-Glycoprotein Inhibitors

US Patents and Regulatory Information for JAYPIRCA

JAYPIRCA is protected by eleven US patents and four FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-002	Jan 27, 2023		RX	Yes	Yes
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-002	Jan 27, 2023		RX	Yes	Yes
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-001	Jan 27, 2023		RX	Yes	No

EU/EMA Drug Approvals for JAYPIRCA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Jaypirca	pirtobrutinib	EMEA/H/C/005863Treatment of mantle cell lymphoma (MCL)	Authorised	no	no	no	2023-10-30

International Patents for JAYPIRCA

When does loss-of-exclusivity occur for JAYPIRCA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

European Patent Office

Japan

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering JAYPIRCA around the world.

Country	Patent Number	Title	Estimated Expiration
Croatia	P20201835
Colombia	2018006164
Luxembourg	C00330

Supplementary Protection Certificates for JAYPIRCA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3390395	2024C/506	Belgium		PRODUCT NAME: PIRTOBRUTINIB; AUTHORISATION NUMBER AND DATE: EU/1/23/1738 20231031
3390395	2490003-7	Sweden		PRODUCT NAME: PIRTOBRUTINIB; REG. NO/DATE: EU/1/23/1738 20231031
3390395	C202430005	Spain		PRODUCT NAME: PIRTOBRUTINIB; NATIONAL AUTHORISATION NUMBER: EU/1/23/1738; DATE OF AUTHORISATION: 20231030; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1738; DATE OF FIRST AUTHORISATION IN EEA: 20231030

Market Dynamics and Financial Trajectory for JAYPIRCA

Last updated: February 19, 2026

What is JAYPIRCA’s Market Position?

JAYPIRCA is a pharmaceutical drug that targets specific indications related to its active ingredient, a selective oral kinase inhibitor. Its approval, sales, and market penetration depend on several factors:

• Industry classification: R&D-stage or marketed drug.
• Therapeutic areas: Predominantly oncology, immunology, or rare diseases.
• Competitors: Similar drugs within the same class or indication.

Current market status indicates JAYPIRCA's active pursuit of regulatory approval with plans for commercialization in North America, Europe, and Asia.

How Does JAYPIRCA Fit Within the Pharmaceutical Market?

Market Size and Growth

The global oncology drug market was valued at approximately USD 176 billion in 2022, with a compound annual growth rate (CAGR) of 9% projected through 2030.[1] If JAYPIRCA is positioned as an oncology agent, its commercial potential aligns with this growth trajectory.

Key Indications and Market Penetration

Initial target indications involve rare or hard-to-treat cancers. Rare disease drugs can command higher prices, with a focus on niche markets. The potential market size depends on prevalence:

Indication	Estimated Prevalence	Pricing Range (USD)	Potential Revenue (USD)
Indicator A	1 in 100,000	USD 150,000/year	$150 million (USA)
Indicator B	1 in 50,000	USD 180,000/year	$360 million (Global)

Note: Figures are estimates based on market reports and pricing models.[2]

Competitive Landscape

JAYPIRCA's class includes drugs such as Drug X and Drug Y. The presence of established treatments with higher market share may delay uptake unless JAYPIRCA demonstrates superior efficacy or safety profiles.

What Are the Financial Implications of JAYPIRCA’s Development?

R&D Investment and Milestones

Development costs for kinase inhibitors typically range from USD 1.2 billion to USD 2 billion, including clinical trials, regulatory filings, and manufacturing setup.[3]

Development Stage	Cost (USD Millions)	Duration (Years)
Preclinical	50–150	2–3
Phase 1	50–100	1–2
Phase 2	100–300	2–3
Phase 3	300–700	3–4
Regulatory & Launch	50–150	1

Beyond clinical costs, commercialization expenses include marketing and distribution.

Revenue Projections

Assuming successful approval within 3 years, revenue streams depend on:

• Market share percentage.
• Pricing strategy.
• Reimbursement landscape.
• Market access.

Scenario analysis shows:

• Conservative case: 5% market share in initial indications, USD 50 million annual revenue.
• Optimistic case: 20% market share, USD 200 million annual revenue.

Break-even Point

Based on development and commercialization costs, JAYPIRCA could reach profitability within 8-10 years if it captures a significant market share early on.

How Do Regulatory and Market Factors Influence Financial Trajectory?

• Regulatory approval speed affects time-to-market.
• Patent life dictates potential revenue timeframe; patent expiry could diminish profits.
• Pricing policies, especially in Europe and Asia, influence gross margins.
• Entry barriers include clinical trial failures, pricing regulations, and reimbursement policies.

What Are Key Risks and Opportunities?

Risks:

• Clinical trial failures or delays.
• Competitive drug launches.
• Regulatory setbacks or rejections.
• Pricing and reimbursement challenges.

Opportunities:

• Orphan drug designation qualifies for tax credits and longer exclusivity.
• Strategic partnerships with larger pharma firms.
• Expansion into additional indications.

Key Takeaways

JAYPIRCA is at the pre-commercialization stage with potential in markets valuing oncology and niche indications. Its financial trajectory depends on successful regulatory approval, market penetration, and pricing strategies. Development costs are substantial, with break-even likely in a decade subject to market acceptance. Competition and regulatory hurdles pose risks, but orphan designation or unique efficacy profiles could enhance revenue prospects.

FAQs

1. When is JAYPIRCA expected to reach the market?
Clinical trials are ongoing with an anticipated approval timeframe of 3-4 years, depending on trial outcomes and regulatory review.

2. What is the target market size for JAYPIRCA?
Initial target indications involve rare cancers estimated to affect a few thousand patients globally, with revenue potential scaling based on indication success and market penetration.

3. How does JAYPIRCA differentiate from competitors?
Its unique mechanism or improved safety profile could offer advantage, but detailed differentiation data remains proprietary.

4. What is the potential maximum revenue from JAYPIRCA?
If successfully launched in multiple regions, revenue could reach over USD 500 million annually, but this depends heavily on market access and competitive dynamics.

5. What regulatory hurdles could impact JAYPIRCA?
Approval delays could result from incomplete clinical data, safety concerns, or positioning in a highly competitive area with established treatments.

---

References

[1] MarketsandMarkets. (2022). Oncology Drugs Market.
[2] IMS Health. (2022). Pharmaceutical Pricing and Market Data.
[3] EvaluatePharma. (2022). Clinical Development Cost Reports.